Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Management Changes Management Comments

Compugen Welcomes Paul Sekhri as its New Chairman of the BoardAugust 2, 2017 7:22 AM Compugen (CGEN) Reports In-Line Q2 EPS; Names Paul Sekhri as ChairmanAugust 2, 2017 7:21 AM